SCHEMBL7518501

SCHEMBL7518501

Cc1ccc(NC(=O)NC2=CC(=O)OC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
MAPT P10636 3/20 0.46
RAB9A P51151 9/20 0.46
NPC1 O15118 8/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
POLB P06746 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PTPN7 P35236 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
TP53 P04637 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
GFER P55789 1/20 0.43
HSD17B10 Q99714 1/20 0.43
EPHX1 P07099 1/20 0.43
GBA1 P04062 1/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7518491 0.86 MAOA (0.50) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL7521385 0.85 MAPT (0.54) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL7514378 0.85 MAOA (0.51) MAPTRAB9ANPC1SMN1; SMN2POLB
SCHEMBL7522725 0.85 RAB9A (0.58) MAPTRAB9ANPC1SMN1; SMN2POLB
SCHEMBL7518242 0.85 KMT2A (0.51) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL7516899 0.85 NPC1 (0.51) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL7519247 0.84 SMN1; SMN2 (0.55) MAPTRAB9ANPC1SMN1; SMN2POLB
SCHEMBL7518859 0.84 EPHX2 (0.48) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL7520625 0.83 PIP4K2A (0.42) RAB9ANPC1SMN1; SMN2LMNA
SCHEMBL7521711 0.83 SMN1; SMN2 (0.52) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents ROCHE DIAGNOSTICS GMBH 2002-05-16 US disclosed
US-6333346-B1 AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 2001-12-25 US disclosed
CN-1278256-A Ureido and thioureido derivatives of 4-amino-2-(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents ROCHE DIAGNOSTICS GMBH (DE) 2000-12-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents UTS2R, SRD5A2, SRD5A1 ALDH1A1 223/4885MAPT 4634/4885RAB9A 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.